Abstract
Direct inhibition of FXa has emerged as an effective strategy to achieve anticoagulation maintaining normal hemostasis with minimal bleeding risks. A novel series of anthranilamide derivatives have been designed and synthesized wherein the bonding order of carbonyl and amino groups of both P1 and P4 motifs in the anthranilamide core structure has been reversed. In order to improve the selectivity for FXa, haloaromatic groups present in the reported FXa inhibitors were retained, while substituted phenylpiperazinylamides were used as S4 binding ligands to improve the physicochemical properties of the resulting compounds. Compounds (6y and 7f) exhibited the most potent FXa inhibitory activities with IC50 values of 0.6 µM and 0.74 µM exhibiting high selectivity over thrombin. Both compounds displayed good anticoagulant activity in rats. Compound (6y) displayed a safety profile similar to the standard drug rivaroxaban in bleeding risk assessment. Simulation studies like molecular docking and molecular dynamics supported strong binding of the analogs to the enzyme FXa
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.